SecProbe.io

CORRESP
1
filename1.htm

              Goodwin Procter LLP

              100 Northern Avenue

                Boston, MA 02210

              T: 617.570.1000

              goodwinprocter.com

    February 7, 2023

    VIA EDGAR

      Office of Real Estate & Construction

      Division of Corporation Finance

      U.S. Securities and Exchange Commission

      100 F. Street, N.E.

      Washington, D.C.  20549

                Attention:

                Joseph Ambrogi

                Maryse Mills-Apenteng

          Re:

            Arrowroot Acquisition Corp.

              Preliminary Proxy Statement on Schedule 14A

              Filed February 2, 2023

              File No. 001-40129

    Ladies and Gentlemen:

    This letter is being submitted on behalf Arrowroot Acquisition Corp. (the “Company”) in response to the comment of the staff of the Division of Corporation Finance (the
      “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) with respect to the Company’s preliminary proxy statement on Schedule 14A filed on February 2, 2023 (the “Preliminary Proxy Statement”), as set forth in
      your letter dated February 7, 2023 (the “Comment Letter”).

    The text of the Comment Letter has been reproduced herein with a response below the numbered comment.  Defined terms used herein but not otherwise defined shall have the
      meaning set forth in the Preliminary Proxy Statement, unless otherwise specified.

    The responses provided herein are based upon information provided to Goodwin Procter LLP by the Company.

    Preliminary Proxy Statement on Schedule 14A filed February 2, 2023

    General

              1.

              With a view toward disclosure, please tell us whether your sponsor is, is controlled by, has any members who are, or has substantial ties with, a
                non-U.S. person. Also revise your filing to include risk factor disclosure that addresses how this fact could impact your ability to complete your initial business combination. For instance, discuss the risk to investors that you may not be
                able to complete an initial business combination with target company should the transaction be subject to review by a U.S. government entity, such as the Committee on Foreign Investment in the United States (CFIUS), or ultimately
                prohibited. Disclose that as a result, the pool of potential targets with which you could complete an initial business combination may be limited. Further, disclose that the time necessary for government review of the transaction or a
                decision to prohibit the transaction could prevent you from completing an initial business combination and require you to liquidate. Disclose the consequences of liquidation to investors, such as the losses of the investment opportunity in
                a target company, any price appreciation in the combined company, and the warrants, which would expire worthless.

    RESPONSE:  We respectfully advise the Staff that the Company’s sponsor is not, is not controlled by, does not have any members who are and does not have substantial ties with,
      a non-U.S. person. As a result, no revision to the disclosure in the Preliminary Proxy Statement is required.

    * * *

      Division of Corporation Finance

      February 7, 2023

      Page 2

    If you have any questions or would like further information concerning the Company’s responses to the Comment Letter, please do not hesitate to contact Jocelyn Arel at (617)
      570-1067 or JArel@goodwinlaw.com.

            Sincerely,

            /s/ Jocelyn Arel

            Goodwin Procter LLP

    cc:          John M. Mutkoski

    Goodwin Procter LLP

    Thomas Olivier

      Matthew Safaii

    Arrowroot Acquisition Corp.